Veru Inc.(VERU)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VERU Veru Inc.

交易中 11-13 09:47:37 EST

2.12

+0.00

+0.00%

最高2.15	最低2.11	成交量1.55万
今开2.15	昨收2.12	日振幅2.12%
总市值3,614万	流通市值3,281万	总股本1,705万
成交额3.32万	换手率0.10%	流通股本1,548万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VERU","market":"US","secType":"STK","nameCN":"Veru Inc.","latestPrice":2.1199,"timestamp":1794581243176,"preClose":2.12,"halted":0,"volume":15479,"delay":0,"changeRate":-0.00004716981132085426,"floatShares":15478466,"shares":17050300,"eps":-0.5854,"marketStatus":"交易中","change":-0.0001,"latestTime":"11-13 09:47:37 EST","open":2.15,"high":2.15,"low":2.105,"amount":33239.6959261,"amplitude":0.021226,"askPrice":2.12,"askSize":441,"bidPrice":2.08,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.5854,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1794603600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.12,"preHourTrading":{"tag":"盘前","latestPrice":2.11,"preClose":2.12,"latestTime":"08:17 EST","volume":3615,"amount":7491.849633,"timestamp":1794575839081,"change":-0.01,"changeRate":-0.004717,"amplitude":0.02},"postHourTrading":{"tag":"盘后","latestPrice":2.0801,"preClose":2.12,"latestTime":"17:53 EST","volume":6510,"amount":13541.85,"timestamp":1794523989717,"change":-0.0399,"changeRate":-0.018821,"amplitude":0.018821},"volumeRatio":3.159684,"impliedVol":0.1798,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/VERU","defaultTab":"news","newsList":[{"id":"1144952887","title":"Veru推进口服Sabizabulin进入计划中的2期临床试验，临床前数据揭示其对Daraxonrasib（Revolution Medicines' Rasonque™）耐药胰腺癌具有强效抗癌活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1144952887","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144952887?lang=zh_cn&edition=full","pubTime":"2026-09-08 20:18","pubTimestamp":1788869895,"startTime":"0","endTime":"0","summary":"Veru公司宣布，基于令人振奋的临床前研究结果，将积极推进口服药物Sabizabulin迈向计划中的2期临床试验阶段。该项研究数据显示，该候选药物在对抗人类Daraxonrasib（即Revolution Medicines旗下Rasonque™）耐药的胰腺癌方面，展现出显著的抗癌效力。这一进展为那些对现有疗法产生耐药性的患者群体带来了新的希望，也标志着Veru在肿瘤治疗领域的布局又向前迈出了坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU","BK4007","BK4584","BK4557","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113446157","title":"Veru Inc. 公布2026财年第三季度财务业绩及2B期Plateau临床试验进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1113446157","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113446157?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:32","pubTimestamp":1786357972,"startTime":"0","endTime":"0","summary":"Veru Inc. 近日发布了其2026财年第三季度的财务报告，同时更新了备受关注的2B期Plateau临床试验的最新进展。这家生物制药公司正稳步推进其核心研发项目，而市场投资者也对其关键疗法管线的未来走向投以密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4557","BK4183","BK4007","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194932615","title":"Veru 宣布关键专利获批：Enobosarm 联合司美格鲁肽用于高质量减重","url":"https://stock-news.laohu8.com/highlight/detail?id=1194932615","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194932615?lang=zh_cn&edition=full","pubTime":"2026-08-04 20:31","pubTimestamp":1785846686,"startTime":"0","endTime":"0","summary":"Veru Inc. 日前正式宣布，已收到美国专利商标局关于其关键用途方法的授权通知。这项专利核心聚焦于Enobosarm与司美格鲁肽的联合应用，旨在实现“高质量减重”——即在减少脂肪的同时，保留肌肉质量。此次专利授权，无疑为Veru在代谢疾病治疗领域的创新布局提供了强有力的法律支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4557","BK4007","VERU","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198429779","title":"Veru 宣布 Enobosarm 与 Semaglutide 联合用药的 2B 期 Plateau 临床试验完成全部入组，旨在实现高质量减重","url":"https://stock-news.laohu8.com/highlight/detail?id=1198429779","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198429779?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:11","pubTimestamp":1785154269,"startTime":"0","endTime":"0","summary":"Veru Inc. 今日宣布，其针对 Enobosarm 与 Semaglutide 联合用药的 2B 期 Plateau 临床试验已实现全面入组。这一试验聚焦于探索该组合在高质量减重方面的潜力，标志着研发进程中的关键里程碑。通过将 Enobosarm 与 Semaglutide 结合，研究旨在降低体重的同时，优先保留肌肉质量，从而提升减重效果的整体质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4183","BK4584","BK4007","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196257291","title":"Veru与奥本海默及Canaccord Genuity达成销售协议，2026年7月2日提交SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1196257291","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196257291?lang=zh_cn&edition=full","pubTime":"2026-07-03 04:12","pubTimestamp":1783023149,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，Veru Inc.已于2026年7月2日与奥本海默公司和Canaccord Genuity正式签署了一项销售协议。该协议的达成标志着Veru在资本运作和股权管理方面迈出了新的一步。文件显示，此项安排旨在为公司未来的融资活动提供更多灵活性，并可能涉及特定数量普通股的销售。此举通常被上市公司用于在公开市场筹集资金，同时优化其资本结构。市场参与者将密切关注后续进展，以评估其对Veru财务状况和股价的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4007","VERU","BK4584","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110985415","title":"Veru授予诺和诺德优先谈判权，涉及恩诺博沙姆与任何诺和诺德GLP-1产品的联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1110985415","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110985415?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:34","pubTimestamp":1780576456,"startTime":"0","endTime":"0","summary":"Veru Inc. 已授予诺和诺德一项优先谈判权，内容涉及将其药物恩诺博沙姆与诺和诺德旗下任何GLP-1产品相结合的联合疗法开发。此项协议为两家公司在代谢疾病治疗领域的潜在合作奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4584","VERU","BK4183","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166835000","title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1166835000","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166835000?lang=zh_cn&edition=full","pubTime":"2025-02-20 17:58","pubTimestamp":1740045485,"startTime":"0","endTime":"0","summary":"罗氏计划今年启动中期试验，将其与自研GLP-1减肥候选药CT-388联用。BiohavenBiohaven在一项早期肥胖试验中评估其靶向肌肉生长抑制素的药物taldefgrobep alfa。该药虽未改善脊髓性肌萎缩症患者的运动功能，但减少了总体脂肪量，并在去脂体重和骨密度方面优于安慰剂。公司将在男性肥胖患者的早期研究中评估安全性，数据预计2025年一季度公布。","market":"us","thumbnail":"https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/f13f2eb23080965f77e2c21530116841"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“减脂不减肌”：药企竞逐下一代减肥药新突破","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","VERU","LLY","KROS","ARWR","AZN","REGN","SRRK","ELAB"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2512827224","title":"Veru Inc.盘中异动 急速上涨5.05%报0.579美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512827224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512827224?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:56","pubTimestamp":1739984170,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时56分，Veru Inc.股票出现波动，股价急速上涨5.05%。截至发稿，该股报0.579美元/股，成交量53.3728万股，换手率0.36%，振幅5.05%。Veru Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220005610988b48c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220005610988b48c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","BK4183","BK4557","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512516732","title":"Veru Inc.盘中异动 急速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512516732","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512516732?lang=zh_cn&edition=full","pubTime":"2025-02-19 00:32","pubTimestamp":1739896345,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日00时32分，Veru Inc.股票出现波动，股价急速上涨5.06%。截至发稿，该股报0.569美元/股，成交量124.164万股，换手率0.85%，振幅8.78%。Veru Inc.股票所在的生物技术行业中，整体涨幅为0.67%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190032259627ac39&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502190032259627ac39&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4183","BK4584","BK4557","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511652650","title":"Veru Inc.盘中异动 股价大跌5.09%报0.522美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511652650","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511652650?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:31","pubTimestamp":1739457068,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时31分，Veru Inc.股票出现波动，股价大幅下挫5.09%。截至发稿，该股报0.522美元/股，成交量152.217万股，换手率1.04%，振幅1.96%。Veru Inc.股票所在的生物技术行业中，整体跌幅为0.01%。其相关个股中，Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 涨幅较大，Tc Biopharm  Plc、Edesa Biotech, Inc.、Genprex, Inc.较为活跃，换手率分别为970.17%、765.03%、89.78%，振幅较大的相关个股有Enliven Therapeutics, Inc.、Rezolute, Inc.、Edesa Biotech, Inc.，振幅分别为7.80%、4.53%、4.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021322310998842b63&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021322310998842b63&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VERU","BK4557","BK4584","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104004542","title":"Veru 第一季度调整后每股收益$(0.07) 超过预期$(0.08)","url":"https://stock-news.laohu8.com/highlight/detail?id=1104004542","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104004542?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:42","pubTimestamp":1739446968,"startTime":"0","endTime":"0","summary":"Veru  报告季度每股亏损$，超过了分析师一致预期的每股亏损$，超出12.5%。相比去年同期每股亏损$，增加了12.5%。以上内容来自Benzinga Earnings专栏，原文如下：Veru  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 12.5 percent. This is a 12.5 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511823546","title":"Veru(VERU.US)：2025年Q1财报实现营收0美元，前值为214.1万美元，预期值为298万美元；每股收益为-0.07美元，前值为-0.08美元，预期值为-0.08美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511823546","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511823546?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:42","pubTimestamp":1739446935,"startTime":"0","endTime":"0","summary":"Veru(VERU.US)：2025年Q1财报实现营收0美元，前值为214.1万美元，预期值为298万美元；每股收益为-0.07美元，前值为-0.08美元，预期值为-0.08美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13194248146640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157057844","title":"Veru公司2025财年第一季度GAAP每股收益为$(0.06)，好于预期$(0.07)，现金及现金等价物为2660万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1157057844","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157057844?lang=zh_cn&edition=full","pubTime":"2025-02-13 19:33","pubTimestamp":1739446411,"startTime":"0","endTime":"0","summary":"Veru公司公布季度每股亏损$，较分析师普遍预期的$高出14.29%。与去年同期的每股亏损$相比，增长了25%。以上内容来自Benzinga Earnings专栏，原文如下：Veru  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 14.29 percent. This is a 25 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veru公司2025财年第一季度GAAP每股收益为$(0.06)，好于预期$(0.07)，现金及现金等价物为2660万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510380942","title":"Veru Inc.盘中异动 股价大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510380942","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510380942?lang=zh_cn&edition=full","pubTime":"2025-02-11 22:50","pubTimestamp":1739285410,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日22时50分，Veru Inc.股票出现异动，股价大幅下挫5.15%。Veru Inc.股票所在的生物技术行业中，整体跌幅为1.52%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2370.36%、645.02%、277.64%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为40.26%、33.04%、33.02%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211225010abcb0a77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211225010abcb0a77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","VERU","BK4183","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509614773","title":"Veru Inc.盘中异动 快速跳水5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509614773","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509614773?lang=zh_cn&edition=full","pubTime":"2025-02-08 03:30","pubTimestamp":1738956645,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日03时30分，Veru Inc.股票出现异动，股价快速下挫5.18%。截至发稿，该股报0.551美元/股，成交量136.703万股，换手率0.93%，振幅8.33%。Veru Inc.股票所在的生物技术行业中，整体跌幅为0.65%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208033045a23d60ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208033045a23d60ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4584","VERU","BK4183","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509565352","title":"Veru Inc.盘中异动 急速上涨5.00%报0.588美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509565352","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509565352?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:33","pubTimestamp":1738787622,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时33分，Veru Inc.股票出现波动，股价大幅拉升5.00%。截至发稿，该股报0.588美元/股，成交量251.646万股，换手率1.72%，振幅8.75%。Veru Inc.股票所在的生物技术行业中，整体涨幅为2.25%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206043342abc3c826&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206043342abc3c826&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4183","BK4557","BK4584","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509286491","title":"Veru Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509286491","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509286491?lang=zh_cn&edition=full","pubTime":"2025-02-05 04:57","pubTimestamp":1738702628,"startTime":"0","endTime":"0","summary":"北京时间2025年02月05日04时57分，Veru Inc.股票出现异动，股价快速下跌5.00%。Veru Inc.股票所在的生物技术行业中，整体涨幅为1.46%。其相关个股中，Mink Therapeutics, Inc.、Cingulate Inc C/Wts 10/12/2026 、Estrella Immunopharma Inc C/Wts 29/09/2028涨幅较大，Azitra Inc、Evaxion Biotech As、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为1968.51%、997.59%、592.78%，振幅较大的相关个股有Azitra Inc、Mink Therapeutics, Inc.、Omega Therapeutics, Inc.，振幅分别为123.99%、80.03%、60.13%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205045708abc26e47&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250205045708abc26e47&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4183","BK4557","VERU","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508639144","title":"Veru Inc.盘中异动 股价大涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508639144","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508639144?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:52","pubTimestamp":1738594339,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时52分，Veru Inc.股票出现波动，股价快速拉升5.27%。截至发稿，该股报0.585美元/股，成交量57.5427万股，换手率0.39%，振幅8.10%。Veru Inc.股票所在的生物技术行业中，整体跌幅为0.54%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225219abc10c20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203225219abc10c20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VERU","BK4557","BK4584","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507562478","title":"Veru Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507562478","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507562478?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:37","pubTimestamp":1738247823,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时37分，Veru Inc.股票出现异动，股价大幅跳水5.10%。截至发稿，该股报0.580美元/股，成交量51.2556万股，换手率0.35%，振幅5.56%。Veru Inc.股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Tectonic Therapeutic, Inc.、Alterity Therapeutics Limited、Kazia Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Alterity Therapeutics Limited、Silexion Therapeutics Corp较为活跃，换手率分别为789.58%、134.25%、112.73%，振幅较大的相关个股有Ocean Biomedical Inc C/Wts 14/02/2028 、Kazia Therapeutics Limited、Tectonic Therapeutic, Inc.，振幅分别为28.90%、28.25%、24.49%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501302237039876b255&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501302237039876b255&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","BK4584","BK4183","VERU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507631266","title":"Veru Inc.盘中异动 早盘快速拉升5.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507631266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507631266?lang=zh_cn&edition=full","pubTime":"2025-01-29 22:31","pubTimestamp":1738161066,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日22时31分，Veru Inc.股票出现波动，股价大幅上涨5.53%。截至发稿，该股报0.550美元/股，成交量48.0583万股，换手率0.33%，振幅0.02%。Veru Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Veru Inc.公司简介：Veru Inc是一家生物制药公司，拥有治疗代谢性疾病、肿瘤学和急性呼吸窘迫综合征的药物开发项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250129223106a23366cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250129223106a23366cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4183","BK4557","VERU","BK4584"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://verupharma.com","stockEarnings":[{"period":"1week","weight":0.0291},{"period":"1month","weight":-0.032},{"period":"3month","weight":-0.2234},{"period":"6month","weight":0.0047},{"period":"1year","weight":-0.2234},{"period":"ytd","weight":-0.0093}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Veru Inc.于1971年在威斯康星州成立。公司是一家临床后期生物制药公司，专注于研发治疗心脏代谢和炎症性疾病的新药。该公司的药物开发计划包括两个晚期新化学实体，enobosarm和sabizabulin。","yearOnYearQuotes":[{"month":1,"riseRate":0.588235,"avgChangeRate":0.00255},{"month":2,"riseRate":0.470588,"avgChangeRate":0.061533},{"month":3,"riseRate":0.352941,"avgChangeRate":-0.044098},{"month":4,"riseRate":0.588235,"avgChangeRate":0.126168},{"month":5,"riseRate":0.529412,"avgChangeRate":0.008998},{"month":6,"riseRate":0.352941,"avgChangeRate":-0.014882},{"month":7,"riseRate":0.388889,"avgChangeRate":-0.025921},{"month":8,"riseRate":0.444444,"avgChangeRate":0.012134},{"month":9,"riseRate":0.388889,"avgChangeRate":-0.011287},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.038041},{"month":11,"riseRate":0.444444,"avgChangeRate":-0.01606},{"month":12,"riseRate":0.235294,"avgChangeRate":0.066456}],"exchange":"NASDAQ","name":"Veru Inc.","nameEN":"Veru Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Veru Inc.(VERU)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Veru Inc.(VERU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Veru Inc.,VERU,Veru Inc.股票,Veru Inc.股票老虎,Veru Inc.股票老虎国际,Veru Inc.行情,Veru Inc.股票行情,Veru Inc.股价,Veru Inc.股市,Veru Inc.股票价格,Veru Inc.股票交易,Veru Inc.股票购买,Veru Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Veru Inc.(VERU)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Veru Inc.(VERU)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}